title: Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.
abstract: Treatment of type 2 diabetes mellitus (T2DM) in older patients is complicated by a variety of factors and requires an individualized approach. Benefits of intensive glycemic control must be weighed against associated risks. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors are newer antihyperglycemic agents that effectively lower glycated hemoglobin levels, with a low risk of hypoglycemia, and have a neutral or beneficial effect on weight. The purpose of this review is to discuss challenges in treating older patients with T2DM, and the efficacy and safety of these newer classes based on clinical trials in older populations.
authors: Professor of Internal Medicine, Chairman, Division of Endocrinology and Metabolism, Department of Internal Medicine, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA.
authors: Jeffrey
authors: J
authors: Freeman
mesh_terms: D000367:Age Factors; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D004347:Drug Interactions; D000067757:Glucagon-Like Peptide-1 Receptor / Q000037:antagonists & inhibitors; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D019338:Polypharmacy; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors